financetom
Business
financetom
/
Business
/
CrowdStrike is sued by fliers after massive outage disrupts air travel
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CrowdStrike is sued by fliers after massive outage disrupts air travel
Aug 5, 2024 3:58 PM

(Reuters) - CrowdStrike's legal troubles from last month's massive global computer outage deepened on Monday, as the cybersecurity company was sued by air travelers whose flights were delayed or canceled.

In a proposed class action filed in the Austin, Texas, federal court, three fliers blamed CrowdStrike's negligence in testing and deploying its software for the outage, which also disrupted banks, hospitals and emergency lines around the world.

The plaintiffs said that as fliers scrambled to get to their destinations, many spent hundreds of dollars on lodging, meals and alternative travel, while others missed work or suffered health problems from having to sleep on the airport floor.

They said CrowdStrike should pay compensatory and punitive damages to anyone whose flight was disrupted, after technology-related flight groundings for Southwest Airlines and other carriers in 2023 made the outage "entirely foreseeable."

CrowdStrike said in a statement: "We believe this case lacks merit and we will vigorously defend the company."

It provided an identical statement in response to a shareholder lawsuit filed on July 31, after the company's stock price had fallen by about one-third.

The outage stemmed from a flawed software update that crashed more than 8 million computers.

Delta Air Lines has said it may take legal action against Austin-based CrowdStrike after canceling more than 6,000 flights, at a cost of about $500 million.

On Sunday, CrowdStrike said it was neither grossly negligent nor at fault for Delta's problems, and that the Atlanta-based carrier did not accept its offer for help.

Delta faces a U.S. Department of Transportation probe into why it needed more time than rivals to recover from the outage.

Monday's case is del Rio et al v CrowdStrike Inc, U.S. District Court, Western District of Texas, No. 24-00881.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--FirstEnergy Raises Quarterly Dividend to $0.425 a Share From $0.41, Payable June 1 to Shareholders of Record May 7
--FirstEnergy Raises Quarterly Dividend to $0.425 a Share From $0.41, Payable June 1 to Shareholders of Record May 7
Mar 20, 2024
12:58 PM EDT, 03/20/2024 (MT Newswires) -- Price: 38.35, Change: +0.05, Percent Change: +0.13 ...
UP Fintech Shares Decline Following Q4 Financial Results
UP Fintech Shares Decline Following Q4 Financial Results
Mar 20, 2024
01:04 PM EDT, 03/20/2024 (MT Newswires) -- UP Fintech Holding ( TIGR ) shares were down 9.5% in recent Wednesday trading after the company reported its Q4 earnings. The company reported Q4 non-GAAP net income of $0.007 per diluted American depositary share, down from $0.029 a year earlier. Revenue for the quarter ended Dec. 31 was $70 million, up from...
CERAWEEK-Williams delays Louisiana natgas pipeline amid competitor dispute
CERAWEEK-Williams delays Louisiana natgas pipeline amid competitor dispute
Mar 20, 2024
HOUSTON, March 20 (Reuters) - U.S. energy firm Williams Companies ( WMB ) has delayed the completion of its Louisiana Energy Gateway natural gas pipeline project following a dispute with a rival, Williams CEO Alan Armstrong said on Wednesday at a conference. The 1.8-billion cubic feet per day (bcfd) pipeline was originally set to come online this year but was...
Design Therapeutics Stock Rises as RBC Says Q4 Results, Product Candidate Updates Show Progress
Design Therapeutics Stock Rises as RBC Says Q4 Results, Product Candidate Updates Show Progress
Mar 20, 2024
01:03 PM EDT, 03/20/2024 (MT Newswires) -- Design Therapeutics ( DSGN ) was trading higher on Wednesday, rising by nearly 9% after reporting a smaller-than-expected Q4 net loss a day earlier and outlining progress with its prospective treatment for Friedreich Ataxia that analysts at RBC Capital Markets said provides the biopharmaceuticals company with a compelling second shot at eventually bringing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved